Your browser doesn't support javascript.
loading
Cost-Effectiveness Analysis of Ofatumumab for the Treatment of Relapsing-Remitting Multiple Sclerosis in Canada.
Baharnoori, Moogeh; Bhan, Virender; Clift, Fraser; Thomas, Kimberly; Mouallif, Soukaïna; Adlard, Nicholas; Cooney, Philip; Blanchette, François; Patel, Barkha P; Grima, Daniel.
Afiliação
  • Baharnoori M; Department of Medicine, Queen's University, Kingston, ON, Canada.
  • Bhan V; Department of Medicine, The University of British Columbia, Vancouver, BC, Canada.
  • Clift F; Department of Neurology, Memorial University of Newfoundland, St. John's, NL, Canada.
  • Thomas K; EVERSANA, Burlington, ON, Canada.
  • Mouallif S; Novartis Canada Inc., 385, boulevard Bouchard, Dorval, QC, H9S 1A9, Canada. soukaina.mouallif@novartis.com.
  • Adlard N; Novartis Pharma AG, Basel, Switzerland.
  • Cooney P; Novartis Ireland Limited, Dublin, Ireland.
  • Blanchette F; Novartis Canada Inc., 385, boulevard Bouchard, Dorval, QC, H9S 1A9, Canada.
  • Patel BP; EVERSANA, Burlington, ON, Canada.
  • Grima D; EVERSANA, Burlington, ON, Canada.
Pharmacoecon Open ; 6(6): 859-870, 2022 Nov.
Article em En | MEDLINE | ID: mdl-36107307
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Health_economic_evaluation / Prognostic_studies Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Health_economic_evaluation / Prognostic_studies Idioma: En Ano de publicação: 2022 Tipo de documento: Article